Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomedica de Barcelona (PRBB), Spain.
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Eur J Pain. 2018 Apr;22(4):763-773. doi: 10.1002/ejp.1161. Epub 2017 Dec 27.
Pregabalin is a first-line agent for neuropathic pain treatment whose abuse liability remains controversial. Surprisingly, studies exploring the reinforcing properties of pregabalin in operant mouse models are missing.
We evaluated the acquisition of operant pregabalin self-administration in mice exposed to a partial sciatic nerve ligation (PSNL) or a sham operation. After surgery, mice were trained in operant boxes to intravenously self-administer pregabalin at 1.5 or 3 mg/kg/inf or saline during 10 days. Thermal and mechanical sensitivity were assessed before and after self-medication, and depressive-like behaviour was evaluated after discontinuation of the treatment.
Partial sciatic nerve ligation and sham-operated mice exposed to pregabalin at 3 mg/kg/inf showed higher active responding compared to mice exposed to saline. The differences in active responding were more robust in nerve-injured than in sham-operated mice. Self-medication at either dose of pregabalin partially inhibited thermal hypersensitivity, whereas only self-medication at 3 mg/kg/inf reduced mechanical sensitivity. Finally, a depressive-like behaviour was revealed after saline treatment in nerve-injured mice, and this emotional manifestation was abolished after pregabalin treatment at the high dose.
Pregabalin showed reinforcing effects both in PSNL and sham-operated mice and attenuated the nociceptive and emotional manifestations of neuropathic pain in mice self-administering this drug. Therefore, pregabalin self-administration was related to neuropathic pain relief, but also to reinforcing properties related to psychotropic drug effects. This study reveals the improvement in nociceptive and emotional manifestations of neuropathic pain after operant pregabalin self-medication in mice and suggests the reinforcing effects of this drug in an operant paradigm.
This study shows that mice with a nerve injury self-administer pregabalin at doses effective reducing nociceptive hypersensitivity and depressive-like behaviour associated with the neuropathic pain model. Interestingly, mice without neuropathy also develop operant self-administration behaviour, suggesting potential abuse liability of this first-line drug for neuropathic pain treatment.
普瑞巴林是治疗神经性疼痛的一线药物,但它的滥用倾向仍存在争议。令人惊讶的是,目前缺乏在操作性老鼠模型中探索普瑞巴林强化特性的研究。
我们评估了暴露于部分坐骨神经结扎(PSNL)或假手术的老鼠对操作性普瑞巴林自我给药的获得情况。手术后,老鼠在操作性箱中接受训练,以 1.5 或 3mg/kg/inf 或生理盐水静脉自我给药 10 天。在自我给药前后评估热和机械敏感性,并在治疗停止后评估抑郁样行为。
暴露于 3mg/kg/inf 普瑞巴林的部分坐骨神经结扎和假手术老鼠与暴露于生理盐水的老鼠相比,表现出更高的主动反应。与假手术老鼠相比,神经损伤老鼠的反应差异更为显著。两种剂量的普瑞巴林自我给药均部分抑制热过敏,但仅 3mg/kg/inf 剂量的自我给药可降低机械敏感性。最后,在神经损伤的老鼠中,生理盐水治疗后出现抑郁样行为,而在高剂量普瑞巴林治疗后,这种情绪表现被消除。
普瑞巴林在 PSNL 和假手术老鼠中均表现出强化作用,并减轻了老鼠自我给药时的神经性疼痛的痛觉和情绪表现。因此,普瑞巴林的自我给药与神经性疼痛的缓解有关,但也与与精神药物作用相关的强化作用有关。本研究揭示了在老鼠操作性普瑞巴林自我给药后,神经性疼痛的痛觉和情绪表现得到改善,并表明这种药物在操作性范式中的强化作用。
这项研究表明,患有神经损伤的老鼠会自行给予有效减轻痛觉过敏和与神经病理性疼痛模型相关的抑郁样行为的普瑞巴林剂量。有趣的是,没有神经病变的老鼠也会产生操作性自我给药行为,这表明这种一线神经性疼痛治疗药物具有潜在的滥用倾向。